Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.48 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.41 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | CBLB | Q13191 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598739 | 0.96 | SCN9A (0.43) | SCN9ASCN3AKCNA2KCNA6NT5E | |
| SCHEMBL13803868 | 0.94 | SCN9A (0.47) | SCN9ASCN3AKCNA2KCNA6NT5E | |
| SCHEMBL12852189 | 0.94 | SCN9A (0.53) | SCN9ASCN3AKCNA2KCNA6NT5E | |
| SCHEMBL12559784 | 0.94 | SCN9A (0.53) | SCN9ASCN3AKCNA2KCNA6NT5E | |
| SCHEMBL12852200 | 0.79 | VIP (0.54) | SCN9ASCN3AKCNA6KCNA3KCNA4 | |
| SCHEMBL12597859 | 0.79 | VIP (0.54) | SCN9ASCN3AKCNA6KCNA3KCNA4 | |
| SCHEMBL12559790 | 0.79 | VIP (0.54) | SCN9ASCN3AKCNA6KCNA3KCNA4 | |
| SCHEMBL12855200 | 0.79 | VIP (0.40) | SCN9ASCN3AKCNA6KCNA3KCNA4 | |
| SCHEMBL12855198 | 0.78 | VIP (0.49) | SCN9ASCN3AKCNA6KCNA3KCNA4 | |
| SCHEMBL12597860 | 0.74 | SCN9A (0.51) | SCN9ASCN3ANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328577-A1 | INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES | MELANDER CHRISTIAN (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328577-A1 | INHIBITION OF BIOFILMS IN PLANTS WITH IMIDAZOLE DERIVATIVES | ITPA, SOD1, ICMT | SCN9A 1732/4885SCN3A 3664/4885KCNA2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.